Project

Cardiovascular disease is the leading cause of death worldwide, among which 15 million people in Europe living with heart failure. Beyond the risk of death, heart failure, whose prevalence continues to rise, has a significant and lasting impact on the health and well-being of patients. Despite huge investments in healthcare, the number of new drugs approved is not increasing. The search for new drugs and devices is particularly challenging due to the significant R&D costs and the complexity of regulatory procedures, thus hampering the commercialization of new solutions, putting patients at risk of not receiving adequate therapy. Additionally, the dramatically increasing attrition rate across all phases of drug and device development pipeline highlights the lack of reliability of both existing preclinical animal models and the current design strategies for clinical trials, urging the need for new predictive tools. Computer modelling and simulation can create scientific evidence based on controlled investigations including satisfying demands for safety, efficacy & improved access.

SimCardioTest project is being funded by the European Commission to develop a standardized and secure cloud-based platform where in-silico trials run seamlessly.